Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Cantargia reports positive results in ongoing phase IIa clinical trial in pancreatic cancer using nadunolimab and chemotherapy

firstwordpharmaMay 21, 2021

Tag: Pancreatic cancer , nadunolimab and chemotherapy , phase IIa clinical trial

PharmaSources Customer Service